Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Prepaid & Other Current

Prepaid & Other Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.22B-22.8%
Eli Lilly logo
Eli LillyLLY
$15.37B-14.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$4.83B+10.7%
Merck & Co. logo
Merck & Co.MRK
$10.77B+7.7%
AbbVie logo
AbbVieABBV
$150M-97.3%
Absci Corporation logo
Absci CorporationABSI
$6.27M+38.2%

Other financials

Income statement

See full
Revenue-
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$9.25B+904%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001636282-26-000050
Line itemMarch 31,2026December 31,2025
CURRENT ASSETS
Cash and cash equivalents$97,185$85,721
Marketable securities644,282670,812
Prepaid expenses and other current assets22,48621,248
Total current assets763,953777,781
TOTAL ASSETS$763,953$777,781
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES

Item 1. Financial Statements (Unaudited).

FAQ

What is Spyre Therapeutics, Inc.'s prepaid & other current?
Spyre Therapeutics, Inc. (SYRE) reported prepaid & other current of $22.49M in Q1 2026.
How has Spyre Therapeutics, Inc.'s prepaid & other current changed year-over-year?
Spyre Therapeutics, Inc.'s prepaid & other current increased by 354.4% year-over-year, from $4.95M to $22.49M.
What is the long-term trend for Spyre Therapeutics, Inc.'s prepaid & other current?
Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s prepaid & other current has grown at a 43.3% compound annual growth rate (CAGR), from $3.52M to $21.25M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.

Ask your AI about Spyre Therapeutics, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude